Invited Review Free radicals and the pathobiology of brain dopamine systems
暂无分享,去创建一个
[1] A. Schapira,et al. Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.
[2] C. Vorhees,et al. Effect of methamphetamine on glutamate‐positive neurons in the adult and developing rat somatosensory cortex , 1996, Synapse.
[3] B. Robinson,et al. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. , 1996, The Journal of clinical investigation.
[4] C. Epstein,et al. Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice , 1996, Brain Research.
[5] C. Epstein,et al. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn‐superoxide dismutase transgenic mice , 1995, Synapse.
[6] M. Naoi,et al. N-methyl(R)salsolinol produces hydroxyl radicals: involvement to neurotoxicity. , 1995, Free radical biology & medicine.
[7] M. Zigmond,et al. Estimating Hydroxyl Radical Content in Rat Brain Using Systemic and Intraventricular Salicylate: Impact of Methamphetamine , 1995, Journal of neurochemistry.
[8] C. Olanow,et al. Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra , 1994, Experimental Neurology.
[9] C. Olanow,et al. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study , 1994, Brain Research.
[10] S. Daniel,et al. Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.
[11] W Slikker,et al. MPTP‐induced oxidative stress and neurotoxicity are age‐dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels , 1994, Synapse.
[12] J. O'Callaghan,et al. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.
[13] D. Sulzer,et al. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[14] S. Snyder,et al. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. , 1994, Science.
[15] C. Epstein,et al. Rapid Communication: Attenuation of Methamphetamine‐Induced Neurotoxicity in Copper/Zinc Superoxide Dismutase Transgenic Mice , 1994, Journal of neurochemistry.
[16] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[17] R. S. Sohal,et al. Relationship between mitochondrial superoxide and hydrogen peroxide production and longevity of mammalian species. , 1993, Free radical biology & medicine.
[18] J. Bockaert,et al. Nitric oxide, superoxide and peroxynitrite: Putative mediators of NMDA-induced cell death in cerebellar granule cells , 1993, Neuropharmacology.
[19] Joseph Loscalzo,et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds , 1993, Nature.
[20] J. Bockaert,et al. NMDA-dependent superoxide production and neurotoxicity , 1993, Nature.
[21] J. Brodkin,et al. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity , 1993, Pharmacology Biochemistry and Behavior.
[22] T. Dawson,et al. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[23] C. Olanow,et al. Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers , 1993, Journal of neuroscience research.
[24] J. Clodfelter,et al. Differing Neurotoxic Potencies of Methamphetamine, Mazindol, and Cocaine in Mesencephalic Cultures , 1993, Journal of neurochemistry.
[25] J. Haines,et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.
[26] M. Colado,et al. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine , 1993, British journal of pharmacology.
[27] T. Koyama,et al. Long-lasting decrease in dopamine uptake sites following repeated administration of methamphetamine in the rat striatum , 1993, Brain Research.
[28] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[29] J. Cadet,et al. The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynatic nigrostriatal markers in the rat , 1992, Brain Research.
[30] C. Nathan,et al. Nitric oxide as a secretory product of mammalian cells , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] G. Kreutzberg,et al. Cytotoxicity of microglia , 1992, Journal of Neuroimmunology.
[32] S. O'dell,et al. MK‐801 protection against methamphetamine‐induced striatal dopamine terminal injury is associated with attenuated dopamine overflow , 1992, Synapse.
[33] D. Ben-shachar,et al. Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats , 1991, Journal of neurochemistry.
[34] A. Heller,et al. Survival of developing dopaminergic neurons in reaggregate tissue culture following treatment with methamphetamine , 1991, Neuroscience Letters.
[35] J. Nash,et al. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. , 1991, European journal of pharmacology.
[36] M. Naoi,et al. Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. , 1991, Biochemical and biophysical research communications.
[37] S. Moncada,et al. Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.
[38] J. Cadet,et al. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.
[39] B. Freeman,et al. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. , 1991, The Journal of biological chemistry.
[40] P Riederer,et al. Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.
[41] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.
[42] D. Dickson,et al. Microglia in human disease, with an emphasis on acquired immune deficiency syndrome. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[43] J. Cadet,et al. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats , 1991, Brain Research Bulletin.
[44] P. Sonsalla,et al. Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. , 1991, The Journal of pharmacology and experimental therapeutics.
[45] G. Jackson,et al. Role of nerve growth factor in oxidant‐antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance , 1990, Journal of neuroscience research.
[46] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[47] J. Cadet,et al. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain , 1989, Brain Research.
[48] J. Cadet,et al. Possible Involvement of Free Radicals in Neuroleptic‐Induced Movement Disorders Evidence from Treatment of Tardive Dyskinesia with Vitamin E , 1989, Annals of the New York Academy of Sciences.
[49] G. C. Wagner,et al. Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.
[50] C. Marsden,et al. A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.
[51] T. Insel,et al. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. , 1989, The Journal of pharmacology and experimental therapeutics.
[52] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[53] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[54] W. Nicklas,et al. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. , 1989, Science.
[55] J. Cadet,et al. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence , 1989, Brain Research.
[56] D. Giulian,et al. Colony-stimulating factors as promoters of ameboid microglia , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[57] Haruhiko Akiyama,et al. Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.
[58] R. Marttila,et al. Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.
[59] B. Logan,et al. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. , 1988, European journal of pharmacology.
[60] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[61] G. Battaglia,et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[62] G. Hanson,et al. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. , 1988, The Journal of pharmacology and experimental therapeutics.
[63] E. D. De Souza,et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.
[64] L S Seiden,et al. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.
[65] G. Hanson,et al. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.
[66] D Giulian,et al. Characterization of ameboid microglia isolated from developing mammalian brain , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[67] I. Fridovich. Biological effects of the superoxide radical. , 1986, Archives of biochemistry and biophysics.
[68] D. Hinshaw,et al. Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. , 1986, The Journal of clinical investigation.
[69] R. Duvoisin,et al. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.
[70] S. Kish,et al. Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.
[71] L. Seiden,et al. Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain , 1985, Brain Research.
[72] R. S. Burns,et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.
[73] L. Seiden,et al. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine , 1984, Pharmacology Biochemistry and Behavior.
[74] R. Duvoisin,et al. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.
[75] K. Chiba,et al. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.
[76] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[77] I. Mavelli,et al. Superoxide dismutase, glutathione peroxidase and catalase in developing rat brain. , 1982, The Biochemical journal.
[78] E. sanders-Bush,et al. Long-term effects of continuous exposure to amphetamine on brain dopamine concentration and synaptosomal uptake in mice. , 1980, European journal of pharmacology.
[79] J. Gibb,et al. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. , 1980, The Journal of pharmacology and experimental therapeutics.
[80] L. Seiden,et al. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study , 1980, Brain Research.
[81] L. Seiden,et al. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.
[82] Sanford P. Markey,et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.
[83] D. Graham. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.
[84] D. Graham,et al. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.
[85] C. Mytilineou,et al. Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. , 1976, The Journal of pharmacology and experimental therapeutics.
[86] G. Cohen,et al. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.
[87] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[88] G. Stern,et al. Tetrahydroisoquinoline Alkaloids: in vivo Metabolites of L-Dopa in Man , 1973, Nature.
[89] S Fahn,et al. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. , 1971, Journal of the neurological sciences.
[90] G. Breese,et al. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. , 1970, The Journal of pharmacology and experimental therapeutics.
[91] E. Roberts. The synapse as a biochemical self--organizing micro-cybernetic unit. , 1966, Brain research.
[92] M. Naoi,et al. Dopamine-Derived Isoquinolines as Dopaminergic Neurotoxins and Oxidative Stress , 1995 .
[93] H. Kolb,et al. Nitric oxide: a pathogenetic factor in autoimmunity. , 1992, Immunology today.
[94] C. J. Schmidt,et al. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.